Molecules to Market launches skin diagnosis system
This article was originally published in Clinica
UK point-of-care specialist Molecules to Market has launched its first product, Dermadex, a computer-based skin diagnosis system in Japan, the UK and US. CEO Peter Keeling says the privately-funded company has identified areas in primary care where costs can be saved by new decision-making tools. This includes diseases with high referral rates, women's health and ageing.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.